The Medical Letter on Drugs and Therapeutics
A Human Papillomavirus Vaccine
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

A recombinant quadrivalent human-papillomavirus-like particle vaccine, Gardasil (Merck), has been approved by the FDA for use in girls and women 9-26 years old to prevent diseases associated with infection with human papillomavirus (HPV) types 6, 11, 16, and 18, including genital warts, precancerous cervical, vaginal or vulvar lesions, and cervical cancer.

BACKGROUND — HPV is sexually transmitted; it is acquired by young women soon after initiation of sexual activity, with a cumulative incidence of 40% within 16 months.1 Although most HPV infections are cleared without clinical sequelae, persistent infection can cause abnormalities in the cervical epithelium that may progress to cancer.

More than 30 types of HPV can infect the genital tract. Types 16 and 18 are responsible for more than 70% of cervical cancers and high-grade cervical intraepithelial neoplasia (CIN), a precursor of ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: A Human Papillomavirus Vaccine
Article code: 1241a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian